Login / Signup

Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.

Benoist ChibaudelMorteza RaeisiRomain CohenGreg YothersRichard M GoldbergJean-Baptiste BachetNorman WolmarkTakayuki YoshinoHans-Joachim E SchmollRachel KerrSara LonardiThomas J GeorgeEinat Shacham-ShmueliQian ShiThierry AndréAimery deGramont
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
No OS benefit of adjuvant OX was found in high-risk stage II CC, regardless of the definition used to characterize tumors as having a high risk for recurrence. Hence, our analysis suggests that OX should not be the standard of care for adjuvant chemotherapy for stage II CC, even in high-risk patients.
Keyphrases
  • end stage renal disease
  • healthcare
  • chronic kidney disease
  • ejection fraction
  • newly diagnosed
  • palliative care
  • peritoneal dialysis
  • prognostic factors
  • quality improvement
  • pain management
  • patient reported